85112-35-2

Usage

Uses

Used in Pharmaceutical Research and Drug Discovery:
4-(4-ETHYL-PHENYL)-THIAZOL-2-YLAMINE is used as a research compound for its potential antifungal and antitumor properties, making it a candidate for the development of new drugs targeting fungal infections and cancer.
Used in Neurological Disorder Treatment:
In the field of neurology, 4-(4-ETHYL-PHENYL)-THIAZOL-2-YLAMINE is used as a dopamine D3 receptor ligand, which is being studied for its potential to treat neurological disorders by modulating dopamine receptor activity.
Used in Antimicrobial Applications:
4-(4-ETHYL-PHENYL)-THIAZOL-2-YLAMINE is used as an antimicrobial agent due to its ability to inhibit the growth of certain microorganisms, which could lead to the development of new treatments for bacterial and other infections.
Used in Antiproliferative Therapy:
4-(4-ETHYL-PHENYL)-THIAZOL-2-YLAMINE is also used in antiproliferative research, where it may help in the development of therapies to control the proliferation of cells, particularly in the context of cancer treatment.

InChI:InChI=1/C11H12N2S/c1-2-8-3-5-9(6-4-8)10-7-14-11(12)13-10/h3-7H,2H2,1H3,(H2,12,13)

Upstream product

• 2632-14-6 4-ethylphenacyl bromide 
• 17356-08-0 thiourea 
• 937-30-4 4-ethylacetophenone 

Downstream Products

• 62684-54-2 2-{[4-(4-ethyl-phenyl)-thiazol-2-ylamino]-(4-p-tolyl-thiazol-2-ylamino)-methyl}-phenol 
• 62684-51-9 2-{bis-[4-(4-ethyl-phenyl)-thiazol-2-ylamino]-methyl}-phenol 
• 1252868-40-8 N-[4-(4-ethylphenyl)-1,3-thiazol-2-yl]-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-5-yl)acetamide 
• 94206-24-3 5-nitro-furan-2-carboxylic acid 4-(4-ethyl-phenyl)-thiazol-2-ylamide 
• 1450832-71-9 C₂₇H₂₁N₃OS 
• 1352646-09-3 C₁₆H₁₉N₃O₃S 
• 313404-00-1 N-[4-(4-Ethylphenyl)thiazol-2-yl]-(2-chloro-5-nitrophenyl)carboxamide 

Relevant academic research and scientific papers

Schiff bases of 4-Phenyl-2-Aminothiazoles as hits to new antischistosomals: Synthesis, in vitro, in vivo and in silico studies

The treatment of schistosomiasis is based on a single drug, the praziquantel (PZQ), an oral bioavailable and efficient agent which causes minimal side effects. The main concern about this approach, however, is that relying on only one drug to treat a helminthic disease is a dangerous strategy since history shows that pathogens easily evolve to resistant forms. Actually, reports about experimental strains exhibiting low sensibility to PZQ can be found in literature. The search for new antischistosomals, consequently, is urgent. Here we report the synthesis of seventeen Schiff bases of 4-(4-Substituted phenyl)-N-(4-substituted benzylidene)thiazole-2-amines which were tested in vitro and in vivo against Schistosoma mansoni adult worms. Moreover, in silico studies to propose potential macromolecular targets and to predict the oral bioavailability were also performed. The analog GPQF-108 exhibited the best in vitro performance (IC50: 29.4 μM, SI:6.1) associated with promising in vivo activity, with a significant decrease in the adult life forms and oviposition. Oral bioavailability could be impaired by the predicted low water solubility of GPQF-108, although it also exhibited good membrane permeability. The water solubility, however, could be improved by decreasing the particles size. Serine/Threonine- and Tyrosine Kinases, Carbonic Anhydrase, Tyrosine Phosphatase and Arginase were predicted as potential macromolecular targets through which the GPQF-108 could be acting against the helminth. This class of compounds exhibited an interesting initial therapeutic profile with the advantage of being chemically diverse from the PZQ and be easily synthesized from commercial reagents which could lead to low-cost drugs. These aspects make this class of compounds interesting hits to be explored against schistosomiasis.

4-Phenyl-1,3-thiazole-2-amines as scaffolds for new antileishmanial agents

Background: There is still a need for new alternatives in pharmacological therapy for neglected diseases, as the drugs available show high toxicity and parenteral administration. That is the case for the treatment of leishmaniasis, particularly to the cutaneous clinical form of the disease. In this study, we present the synthesis and biological screening of eight 4-phenyl-1,3-thiazol-2-amines assayed against Leishmania amazonensis. Herein we propose that these compounds are good starting points for the search of new antileishmanial drugs by demonstrating some of the structural aspects which could interfere with the observed activity, as well as suggesting potential macromolecular targets. Methods: The compounds were easily synthesized by the methodology of Hantzsch and Weber, had their purities determined by Gas Chromatography-Mass spectrometry and assayed against the promastigote forms of Leishmania amazonensis as well as against two white cell lines (L929 and THP-1) and the monkey's kidney Vero cells. PrestoBlue and MTT viability assays were the methodologies applied to measure the antileishmanial and cytotoxic activities, respectively. A molecular modeling target fishing study was performed aiming to propose potential macromolecular targets which could explain the observed biological behavior. Results: Four out of the eight compounds tested exhibited important anti-promastigote activity associated with good selectivity indexes when considering Vero cells. For the most promising compound, compound 6, IC50 against promastigotes was 20.78 while SI was 5.69. Compounds 3 (IC50: 46.63μM; SI: 26.11) and 4 (IC50: 53.12μM; SI: 4.80) also presented important biological behavior. A target fishing study suggested that S-methyl-5-thioadenosine phosphorylase is a potential target to these compounds, which could be explored to enhance activity and decrease the potential toxic side effects. Conclusions: This study shows that 4-phenyl-1,3-thiazol-2-amines could be good scaffolds to the development of new antileishmanial agents. The S-methyl-5-thioadenosine phosphorylase could be one of the macromolecular targets involved in the action.

Citric Acid-catalyzed Synthesis of 2,4-Disubstituted Thiazoles from Ketones via C–Br, C–S, and C–N Bond Formations in One Pot: A Green Approach

An improved and greener protocol has been developed for the synthesis of 2,4-disubstituted thiazoles via C–Br, C–S, and, C–N bond formations in a single step from readily available ketones, N-bromosuccinimide (NBS), and thiourea catalyzed by citric acid in a mixture of ethanol and water (3:1) under reflux conditions. This method has the advantages of freedom from the isolation of lachrymatory α-bromoketones, ease of carrying out, cleaner reaction profile, broad substrate scope, freedom from chromatographic purification, and suitability for large-scale synthesis.

Synthesis and anticancer evaluation of 3-aryl-6-phenylimidazo[2,1-b]thiazoles

A series of new 3,6-diphenylimidazo[2,1-b]thiazole derivatives (4a-l) are synthesized and evaluated for their anticancer activity. Some of the synthesized compounds have shown potent anti-proliferative activity against HeLa, MDA-MB-231, A549 and THP1 huma

PYRIMIDINEDIONE-FUSED HETEROCYCLIC COMPOUNDS AS TRPA1 MODULATORS

The present invention is related to novel pyrimidinedione-fused heterocyclic compounds as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.

QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS

The present invention provides Quinazolinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by T